Clinical Trials Browser

Terminated × INDUSTRY × TAK-659 × Clear all

NCT02323113 2023-02-08

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Phase 1/2 Terminated

43 enrolled 27 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02834247 2023-02-08

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase 1 Terminated

41 enrolled 24 charts

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT03123393 2023-02-08

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Terminated

49 enrolled 12 charts

Lymphoma, Large B-Cell, Diffuse

NCT03238651 2023-02-08

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Phase 1 Terminated

17 enrolled 24 charts

Lymphoma, Lymphoma, Non-Hodgkin

NCT02954406 2022-02-18

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Phase 1 Terminated

43 enrolled 27 charts

Lymphoma, Non-Hodgkin